A 28-year-old woman from Delhi presents to the gynaecology clinic requesting contraception. She has a 3-year history of migraine with aura, occurring 2–3 times per month, typically preceded by visual scotomata and photophobia. Her menarche was at age 12, cycles are regular (28 days), and she has no other medical comorbidities. She is a non-smoker and has never been pregnant. On examination, vital signs are normal and neurological examination is unremarkable. She asks about starting combined oral contraceptive pills (COCPs). What is the most appropriate counselling regarding COCPs in this patient?

Explanation

## Clinical Context This patient has **migraine with aura** — a key contraindication to combined oral contraceptive pills. The presence of aura (visual scotomata, photophobia) is the critical distinguishing feature that elevates her stroke risk. ## Mechanism of Increased Risk **Key Point:** Migraine with aura is associated with a 2–4-fold increased risk of ischaemic stroke, particularly in women aged 20–45 years. The aura phase involves transient cortical spreading depression and transient cerebral hypoperfusion. Combined estrogen-progestin formulations further elevate thrombotic risk by increasing coagulation factors (II, VII, X) and decreasing anticoagulants (protein S, antithrombin III). ## WHO Medical Eligibility Criteria (MEC) | Contraceptive Method | Migraine with Aura | Migraine without Aura | |---|---|---| | **Combined OCP** | **Category 4 (Contraindicated)** | Category 2 (Use with caution) | | **Progestin-only pill (POP)** | Category 2 (Acceptable) | Category 1 (Unrestricted) | | **IUD (Cu or LNG)** | Category 1 (Unrestricted) | Category 1 (Unrestricted) | | **Barrier methods** | Category 1 (Unrestricted) | Category 1 (Unrestricted) | **High-Yield:** The distinction between migraine **with aura** (contraindicated for COCPs) and migraine **without aura** (acceptable with caution) is critical in NEET PG. Aura is the presence of transient focal neurological symptoms (visual, sensory, motor, speech disturbance) preceding the headache. ## Counselling Approach **Clinical Pearl:** Counsel the patient that: 1. COCPs are **absolutely contraindicated** due to stroke risk. 2. **Safe alternatives** include progestin-only pills (minipill), copper or LNG-IUD, barrier methods, or permanent methods. 3. If she chooses a progestin-only method, counsel on irregular bleeding and need for consistent timing. ## Why Not Low-Dose COCPs? ~~Even low-dose COCPs (≤30 μg ethinyl estradiol) do not eliminate the stroke risk in migraine with aura.~~ The estrogen component, regardless of dose, interacts with the underlying migraine-aura pathophysiology to increase thrombotic events. This is a common misconception in clinical practice. **Warning:** Do NOT offer COCPs to any woman with confirmed migraine with aura, regardless of dose, frequency of migraines, or age — it is a Category 4 (contraindicated) condition per WHO MEC.